1. American Heart Association. 1997 Heart and Stroke Statistical Update. 1997.
2. Mark DB. Medical economics in cardiovascular medicine. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. New York: Lippincott-Raven, 1997; In press.
3. Mark DB, Cowper PA, Berkowitz S, Davidson-Ray L, DeLong ER, Turpie AGG, Califf RM, Weatherly B, Lee KL, Cohen M. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Submitted..
4. Cost Effectiveness in Health and Medicine;Gold,1996
5. Konstam MA, Dracup K, Baker DW, Bottorff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF, Hadorn DC. Clinical Practice Guideline XI: Heart Failure: evaluation and care of patients with left-ventricular systolic dysfunction. AHCPR 1994; No. 94-0612.